| Mr Joseph Anthony Kister, AA-C | |
|
615 S New Ballas Rd, Saint Louis, MO 63141-8221 | |
| (314) 251-6000 | |
| (636) 386-7679 |
| Full Name | Mr Joseph Anthony Kister |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology Assistant |
| Experience | 10 Years |
| Location | 615 S New Ballas Rd, Saint Louis, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386046878 | NPI | - | NPPES |
| 1386046878 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 2014032277 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Louis University Hospital | Saint louis, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ssm Health Slu Hospital Anesthesia Physician Billing Llc | 3274842331 | 77 |
News Archive
Foods that contain acrylamide are unlikely to cause breast cancer in women, according to preliminary results of a new study involving 100,000 U.S. women.
Men with certain scores and patterns based on prostate cancer biopsy were found to be at higher risk of PSA-failure, suggesting that this measurement could help predict the risk of prostate cancer recurrence, according to preliminary research published in the October 3 issue of JAMA.
The William and Ella Owens Medical Research Foundation has awarded Texas Biomed Associate Professor Marcel Daadi, Ph.D., with a grant of more than $100,000 to test a promising FDA-approved drug for reversing age-related cognitive decline and memory deficits observed in aged baboons.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.
Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal "rapid-aging" disease, demonstrate the efficacy of a farnesyltransferase inhibitor (FTI), a drug originally developed to treat cancer. The clinical trial results, completed only six years after scientists identified the cause of Progeria, included significant improvements in weight gain, bone structure and, most importantly, the cardiovascular system, according to The Progeria Research Foundation (PRF) and Boston Children's Hospital.
› Verified 5 days ago
| Entity Name | Ssm Health Slu Hospital Anesthesia Physician Billing Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407232804 PECOS PAC ID: 3274842331 Enrollment ID: O20151013000437 |
News Archive
Foods that contain acrylamide are unlikely to cause breast cancer in women, according to preliminary results of a new study involving 100,000 U.S. women.
Men with certain scores and patterns based on prostate cancer biopsy were found to be at higher risk of PSA-failure, suggesting that this measurement could help predict the risk of prostate cancer recurrence, according to preliminary research published in the October 3 issue of JAMA.
The William and Ella Owens Medical Research Foundation has awarded Texas Biomed Associate Professor Marcel Daadi, Ph.D., with a grant of more than $100,000 to test a promising FDA-approved drug for reversing age-related cognitive decline and memory deficits observed in aged baboons.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.
Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal "rapid-aging" disease, demonstrate the efficacy of a farnesyltransferase inhibitor (FTI), a drug originally developed to treat cancer. The clinical trial results, completed only six years after scientists identified the cause of Progeria, included significant improvements in weight gain, bone structure and, most importantly, the cardiovascular system, according to The Progeria Research Foundation (PRF) and Boston Children's Hospital.
› Verified 5 days ago
| Entity Name | Ssm Health Care Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306589544 PECOS PAC ID: 0143608372 Enrollment ID: O20220531002655 |
News Archive
Foods that contain acrylamide are unlikely to cause breast cancer in women, according to preliminary results of a new study involving 100,000 U.S. women.
Men with certain scores and patterns based on prostate cancer biopsy were found to be at higher risk of PSA-failure, suggesting that this measurement could help predict the risk of prostate cancer recurrence, according to preliminary research published in the October 3 issue of JAMA.
The William and Ella Owens Medical Research Foundation has awarded Texas Biomed Associate Professor Marcel Daadi, Ph.D., with a grant of more than $100,000 to test a promising FDA-approved drug for reversing age-related cognitive decline and memory deficits observed in aged baboons.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.
Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal "rapid-aging" disease, demonstrate the efficacy of a farnesyltransferase inhibitor (FTI), a drug originally developed to treat cancer. The clinical trial results, completed only six years after scientists identified the cause of Progeria, included significant improvements in weight gain, bone structure and, most importantly, the cardiovascular system, according to The Progeria Research Foundation (PRF) and Boston Children's Hospital.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Joseph Anthony Kister, AA-C Po Box 505164, Saint Louis, MO 63150-5164 Ph: (417) 829-4620 | Mr Joseph Anthony Kister, AA-C 615 S New Ballas Rd, Saint Louis, MO 63141-8221 Ph: (314) 251-6000 |
News Archive
Foods that contain acrylamide are unlikely to cause breast cancer in women, according to preliminary results of a new study involving 100,000 U.S. women.
Men with certain scores and patterns based on prostate cancer biopsy were found to be at higher risk of PSA-failure, suggesting that this measurement could help predict the risk of prostate cancer recurrence, according to preliminary research published in the October 3 issue of JAMA.
The William and Ella Owens Medical Research Foundation has awarded Texas Biomed Associate Professor Marcel Daadi, Ph.D., with a grant of more than $100,000 to test a promising FDA-approved drug for reversing age-related cognitive decline and memory deficits observed in aged baboons.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.
Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal "rapid-aging" disease, demonstrate the efficacy of a farnesyltransferase inhibitor (FTI), a drug originally developed to treat cancer. The clinical trial results, completed only six years after scientists identified the cause of Progeria, included significant improvements in weight gain, bone structure and, most importantly, the cardiovascular system, according to The Progeria Research Foundation (PRF) and Boston Children's Hospital.
› Verified 5 days ago
Jeremy Stephen Colyer, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 10010 Kennerly Rd, Saint Louis, MO 63128 Phone: 636-386-7222 Fax: 636-200-4036 | |
Mrs. Maria Jones, C-AA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 615 S New Ballas Rd Dept Of, Saint Louis, MO 63141 Phone: 636-386-9224 Fax: 636-200-4243 | |
Alexander Sextro, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 11133 Dunn Rd, Saint Louis, MO 63136 Phone: 314-653-5000 | |
Alexis Haas Stewart, Anesthesiologist Assistant Medicare: May Accept Medicare Assignments Practice Location: 1465 S Grand Blvd, Saint Louis, MO 63104 Phone: 314-977-5700 | |
Mr. Brian J Ho, A.A. Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 615 S New Ballas Rd, Dept. Of Anesthesiology, Saint Louis, MO 63141 Phone: 314-251-4687 Fax: 636-200-4243 | |
Laheart Marie Rodney, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1465 S Grand Blvd, Saint Louis, MO 63104 Phone: 314-268-7267 | |
Mr. Nick Balarama Rodriguez, AA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 615 S New Ballas Rd Dept Of, Saint Louis, MO 63141 Phone: 636-386-9224 Fax: 636-386-7679 |